Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma

Ronchi, L.; Buwenge, M.; Cortesi, A.; Ammendolia, I.; Frakulli, R.; Abate, Massimo Eraldo; Arcelli, A.; Donati, Costanza Maria; Macchia, G.; Morganti, Alessio Giuseppe; Cammelli, S.

doi:10.21873/anticanres.12816

Cited by 17 publications

(29 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SBRT for control of pulmonary metastases using median dose of 54 Gy in 3‐4 fractions results in excellent local control of 95% with minimal toxicity 41 . Unlike Ewing sarcoma, whole lung irradiation is not part of standard of care for lung metastases in osteosarcoma patients 42 …”

Section: Osteosarcoma Treatment In North Americamentioning

confidence: 99%

Osteosarcoma

Eaton

Schwarz

Vatner

et al. 2020

Pediatric Blood & Cancer

147

View full text Add to dashboard Cite

Osteosarcoma is a rare tumor that requires complex multidisciplinary management. This paper reviews the general management and standard radiotherapy guidelines for osteosarcoma in both North America and Europe in a joined effort between the Children's Oncology Group and International Society of Pediatric Oncology. Standard treatment involves multiagent induction chemotherapy followed by surgical resection for local tumor control and consolidation local control to metastatic sites. Radiotherapy is reserved for cases with a marginal or incomplete resection or for definitive treatment in the case of unresectable disease. We present supporting data for the role of chemotherapy, surgery, and radiation therapy.

show abstract

Section: Osteosarcoma Treatment In North Americamentioning

confidence: 99%

Osteosarcoma

Eaton

Schwarz

Vatner

et al. 2020

Pediatric Blood & Cancer

147

View full text Add to dashboard Cite

show abstract

“…[10][11][12][13][14][15] In addition to playing a role in primary tumour control, radiation therapy is an important tool in the palliative management of localized and metastatic canine and human bone sarcomas. [16][17][18][19][20][21][22] Treatment of human osteosarcoma and Ewing sarcoma is complicated, in part due to the lack of prospective, randomized trials beyond first-line therapy, and there is a clear need for the development of new approaches to improve clinical outcomes. 9,23 The costs of new drug discovery efforts, particularly for paediatric tumours like osteosarcoma, are often prohibitive, leading to an interest in repurposing existing FDA-approved drugs if they demonstrate anticancer activity.…”

Section: Inroductionmentioning

confidence: 99%

“…These features allow the dog to be an appropriate large animal model of spontaneous bone sarcoma . In addition to playing a role in primary tumour control, radiation therapy is an important tool in the palliative management of localized and metastatic canine and human bone sarcomas . Treatment of human osteosarcoma and Ewing sarcoma is complicated, in part due to the lack of prospective, randomized trials beyond first‐line therapy, and there is a clear need for the development of new approaches to improve clinical outcomes .…”

Section: Inroductionmentioning

confidence: 99%

The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells

Duckett

Phung

Linh-Trung

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

Adrenergic receptor (AR) expression has been demonstrated at several sites of primary and metastatic tumour growth and may influence proliferation, survival, metastasis and angiogenesis. AR antagonists like propranolol and carvedilol inhibit proliferation, induce apoptosis and synergize with chemotherapy agents in some cancers. Radiation resistance is mediated in many cells by upregulation of pro‐survival pathways, which may be influenced by ARs. Studies evaluating AR antagonists combined with radiation are limited. The purpose of this study was to determine the effect of propranolol and carvedilol on viability and radiosensitivity in sarcoma cell lines. The hypothesis was that propranolol and carvedilol would increase radiosensitivity in four primary bone sarcoma cell lines. Single agent propranolol or carvedilol inhibited cell viability in all cell lines in a concentration‐dependent manner. The mean inhibitory concentrations (IC50) for carvedilol were approximately 4‐fold lower than propranolol and may be clinically relevant in vivo. Immunoblot analysis confirmed AR expression in both human and canine sarcoma cell lines; however, there was no correlation between baseline AR protein expression and radiosensitivity. Short duration treatment with carvedilol and propranolol did not significantly affect clonogenic survival. Prolonged exposure to propranolol and carvedilol significantly decreased the surviving fraction of canine osteosarcoma cells after 3Gy radiation. Based on our results and possible in vivo activity in dogs, further studies investigating the effects of carvedilol on sarcoma are warranted.

show abstract

“…However, the long-term prognosis of patients with osteosarcoma is still poor. Approximately 80% of patients had recurrences after surgical treatment, and factors such as early lung metastasis and postoperative tumor recurrence were still bothering orthopedic clinicians [6]. Currently, the long-term survival rate of patients with recurrent osteosarcoma is less than 20%, although several molecular targeted drugs have emerged, none of them can be well used in the treatment of osteosarcoma, the emergence of chemotherapeutic drug resistance and side effects of chemotherapeutic drugs such as hepatoxicity, nephrotoxicity and cardiotoxicity [7].…”

Section: Introductionmentioning

confidence: 99%

Relationship between red cell distribution width and prognosis of patients with osteosarcoma

2019

View full text Add to dashboard Cite

We retrospectively collected the clinical data and follow-up information of patients with osteosarcoma who were admitted to Department of Orthopedics, RenMin Hospital of Wuhan University from January 2010 to December 2016 and explore the relationship between red cell distribution width (RDW) and prognosis of patients with osteosarcoma. The present study finally included 271 patients with osteosarcoma with median follow-up time of 24.2 months (3–69 months). According to the RDW median, 135 patients belong to the low RDW group and 136 patients belong to high RDW group. Compared with low RDW group, the high RDW group tend to have metastasis (50 vs 32.6%, P=0.004), higher poor response rate to chemotherapy compared with the low RDW group (24.3 vs 7.4%, P=0.000) and higher C-reactive protein (CRP) (7.6 ± 4.9 vs 5.5 ± 4.5, t = 3.727, P=0.000). There was slightly significant difference in the types of pathology (χ2 = 8.059, P=0.045). The Kaplan–Meier analysis indicated survival curve of high RDW group was poorer than that in the low RDW group (P=0.020). The univariate cox analysis indicated that patients with RDW ≥ median had higher risk of poor prognosis compared with those who had RDW level < median (HR = 2.41, 95% confidence interval (CI): 1.51–3.83, P=0.000). After adjusting some potential cofounding factors, the elevated RDW was still associated with poor prognosis (HR = 1.66, 95% CI: 1.07–2.56, P=0.024). The elevated pretreatment RDW was associated with poor overall survival (OS) in patients with osteosarcoma and can be an independent predictor of prognosis.

show abstract

Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma

Cited by 17 publications

References 18 publications

Osteosarcoma

Osteosarcoma

The adrenergic receptor antagonists propranolol and carvedilol decrease bone sarcoma cell viability and sustained carvedilol reduces clonogenic survival and increases radiosensitivity in canine osteosarcoma cells

Relationship between red cell distribution width and prognosis of patients with osteosarcoma

Contact Info

Product

Resources

About